(MENAFN- Baystreet) Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles
Smart Agriculture Poised for Growth, Set to Hit $36.24 Billion by 2030
Dick's, NIKE to Host“It's Her Shot” Tour
GM Can Regain Market Share in China, Says Chief
Oracle Named Industry Leader, Shares Fall Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkins - Thursday, May 9, 2024
Virios Reveals Figures, Corporate Update
Atlanta-bsed Virios Therapeutics, Inc. (NASDAQ: VIRI) shares dwindled as the company today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
Research and development expenses for the first quarter of 2024 were $0.3 million, compared to $0.5 million for the first quarter of 2023. The quarter-over-quarter change was due to decreases in expenses for toxicology studies of $0.1 million and regulatory consulting costs of $0.1 million.
General and administrative expenses for the first quarter of 2024 were $1.0 million, compared to $1.1 million for the first quarter of 2023. The quarter-over-quarter change was primarily due to a decrease in insurance expenses associated with being a public company.
Net loss for the first quarter of 2024 was $1.3 million, or $0.07 basic and diluted net loss per share, compared to a net loss of $1.5 million, or $0.08 basic and diluted net loss per share, for the first quarter of 2023.
The Company continues to actively explore complementary opportunities that will build shareholder value through strategic partnerships, collaborations or other transactions.
Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia and Long-COVID.
VIRI shares dropped five cents, or 10.9%, to 38 cents.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN09052024000212011056ID1108195497
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.